Literature DB >> 9075762

Re-examination of clinical manifestations and response to therapy of fissure-in-ano.

N Hananel1, P H Gordon.   

Abstract

PURPOSE: This study was designed to reassess clinical manifestations of fissure-in-ano, in particular, the frequency of constipation and rate of response to medical management.
METHODS: Records of 876 patients with fissure-in-ano seen between February 1975 and December 1993 were reviewed. Information gathered included age, gender, site, symptoms, bowel habits, associated anorectal problems, response, failure, and recurrence rates.
RESULTS: There were 439 women (51.1 percent) and 437 men (49.9 percent); mean age was 39.9 (range, 13.5-95) years. The fissure was located in the posterior mid line in 644 patients (73.5 percent), the anterior mid line in 144 patients (16.4 percent), both in 23 patients (2.6 percent), and only tenderness documented in 65 patients (7.4 percent). The fissure was located in the anterior midline in 12.6 percent of women and 7.7 percent of men. Dominant presenting symptoms included pain in 90.8 percent and bleeding in 71.4 percent of patients. Infrequent hard bowel movements (> or = 3 days) occurred in only 13.8 percent of patients. Mean follow-up was 26 (range, 0.5-215) months. A total of 44.7 percent of patients responded to nonoperative therapy, 60 percent of them in the first two months; of these, 18.6 percent developed recurrent symptoms. Of the latter group, 60 percent responded to further medical therapy, and 20 percent underwent a lateral internal sphincterotomy. Of the patients who initially did not respond to medical treatment (50.5 percent), lateral internal sphincterotomy was recommended.
CONCLUSION: Anterior fissures are much more common in both men and women than previously reported, and constipation and hard bowel movement are not universally present in patients with fissure-in-ano.

Entities:  

Mesh:

Year:  1997        PMID: 9075762     DOI: 10.1007/bf02054993

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  17 in total

1.  Anal fissure.

Authors:  Karen N Zaghiyan; Phillip Fleshner
Journal:  Clin Colon Rectal Surg       Date:  2011-03

Review 2.  A review of chronic anal fissure management.

Authors:  E E Collins; J N Lund
Journal:  Tech Coloproctol       Date:  2007-08-03       Impact factor: 3.781

Review 3.  Anal fissure.

Authors:  Steven Schlichtemeier; Alexander Engel
Journal:  Aust Prescr       Date:  2016-02-01

Review 4.  Anal Fissure.

Authors:  Jennifer Sam Beaty; M Shashidharan
Journal:  Clin Colon Rectal Surg       Date:  2016-03

5.  Stability of Hydrocortisone, Nifedipine, and Nitroglycerine Compounded Preparations for the Treatment of Anorectal Conditions.

Authors:  Mihaela Friciu; Amandine Chefson; Grégoire Leclair
Journal:  Can J Hosp Pharm       Date:  2016-08-31

6.  Myoxinol ointment for the treatment of acute fissure.

Authors:  J Martellucci; G Rossi; I Corsale; P Carrieri; M D'Elia; I Giani
Journal:  Updates Surg       Date:  2017-04-22

7.  [Lateral, partial sphincter myotomy as therapy of chronic anal fissue. Long-term outcome of an epidemiological cohort study].

Authors:  C Hasse; M Brune; S Bachmann; W Lorenz; M Rothmund; H Sitter
Journal:  Chirurg       Date:  2004-02       Impact factor: 0.955

8.  Glyceryl trinitrate ointment (0.25%) and anal cryothermal dilators in the treatment of chronic anal fissures.

Authors:  Michele Schiano di Visconte; Gabriele Munegato
Journal:  J Gastrointest Surg       Date:  2009-04-15       Impact factor: 3.452

9.  Quality of compounded topical 2% diltiazem hydrochloride formulations for anal fissure.

Authors:  Monil Shah; Laura Sandler; Vishwas Rai; Charu Sharma; Lakshmi Raghavan
Journal:  World J Gastroenterol       Date:  2013-09-14       Impact factor: 5.742

10.  Nonsurgical treatment of chronic anal fissure: nitroglycerin and dilatation versus nifedipine and botulinum toxin.

Authors:  Philippe Tranqui; Daniel C Trottier; Charles Victor; Joel B Freeman
Journal:  Can J Surg       Date:  2006-02       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.